文献速递免疫规划传染病防控与疫情报告

十价肺炎球菌结合疫苗对2岁以下儿童侵袭性肺炎球菌病的效果:孟加拉国农村前瞻性人群研究

Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
PubMed 文献 · Vaccine · 2023-12-08

在孟加拉国Mirzapur农村地区对2-<24月龄儿童开展2012年4月至2019年3月的人群监测,比较PCV10引入前后IPD和重症肺炎发生率。血培养确诊24例IPD、1704例重症肺炎住院;IPD发生率下降25%(95%CI:-1.2%至76%;p=0.59),疫苗血清型IPD下降77%(95%CI:-0.45%至96%;p=0.068),重症肺炎住院显著下降54.0%(95%CI:47.0%至59.0%;p<0.001)。间接队列分析显示PCV10对疫苗血清型IPD的效果在第1剂后为37%(95%CI:-141.0%至83.5%;p=0.5),第2或第3剂后为63.1%(95%CI:-3.3%至85.9%;p=0.0411)。

要点

  • PCV10引入后重症肺炎住院显著下降54.0%(95%CI:47.0%至59.0%;p<0.001)。
  • IPD总发生率下降25%(95%CI:-1.2%至76%;p=0.59),未达统计学显著。
  • 疫苗血清型IPD下降77%(95%CI:-0.45%至96%;p=0.068),未达统计学显著。

核心结论

  • 本研究表明PCV10引入预防了重症肺炎住院,并对疫苗血清型提供个体保护。

研究设计与样本

  • 在孟加拉国Mirzapur农村分县对2-<24月龄儿童开展2012年4月至2019年3月的前瞻性人群监测。
  • 比较PCV10引入前(2012年4月至2015年3月)与引入后(2015年4月至2019年3月)IPD和重症肺炎发生率。
  • 采用间接队列分析,在四个哨点比较疫苗血清型IPD与非疫苗血清型IPD儿童的PCV10接种状态以测量疫苗效果。

主要发现

  • 监测期间血培养确诊24例IPD、1704例重症肺炎住院。
  • 2岁以下儿童IPD发生率从基线106例/10万儿童年降至2018年4月至2019年3月的79.3例/10万儿童年,下降25%(95%CI:-1.2%至76%;p=0.59)。
  • 疫苗血清型IPD发生率从接种前85.7例/10万儿童年降至2018年4月至2019年3月的19.8例/10万儿童年,下降77%(95%CI:-0.45%至96%;p=0.068)。
  • 重症肺炎住院下降54.0%(95%CI:47.0%至59.0%;p<0.001)。
  • 间接队列分析中PCV10对疫苗血清型IPD的效果第1剂后为37%(95%CI:-141.0%至83.5%;p=0.5),第2或第3剂后为63.1%(95%CI:-3.3%至85.9%;p=0.0411)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in March 2015 in Bangladesh. In this study, we aimed to estimate the impact of PCV10 on invasive pneumococcal disease (IPD) identified by blood cultures and severe pneumonia identified clinically and its effectiveness on invasive disease caused by vaccine serotypes. We conducted population-based surveillance among children aged 2- <24 months between April 2012 through March 2019 in Mirzapur, a rural sub-district of Bangladesh. We compared incidence of IPD and severe pneumonia before (April 2012 to March 2015) and after (April 2015 to March 2019) the introduction of PCV10. Vaccine effectiveness was measured using an indirect cohort analysis of data from four sentinel sites in which PCV10 vaccination status was compared between children with IPD caused by vaccine serotype vs. non-vaccine serotypes. We identified 24 IPD cases by blood culture and 1,704 severe pneumonia hospitalizations during the surveillance period. IPD incidence in under-2-year-old children fell 25 % (95 % CI: -1.2 % to 76 %; p-value = 0.59) from 106 cases per 100,000 child-years at baseline to 79.3 in April 2018- March 2019. Vaccine serotype-IPD incidence was lower (77 % reduction, 95 % CI: -0.45 % to 96 %; p-value = 0.068) in April 2018 - March 2019 than in the pre-vaccine period (85.7 cases to 19.8/100,000 child-years). A significant decline of 54.0 % (95 % CI: 47.0 % to 59.0 %; p-value < 0.001) was observed in hospitalizations due to severe pneumonia. From indirect cohort analysis, the effectiveness of PCV10 against vaccine serotype IPD was 37 % (95 % CI: -141.0 % to 83.5 %; p = 0.5) after the 1st dose and 63.1 % (95 % CI: -3.3 % to 85.9 %, p = 0.0411) after the 2nd or the 3rd dose. This study demonstrates that PCV10 introduction prevented hospitalizations with severe pneumonia and provided individual protection against vaccine serotypes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Malaker R, Hasanuzzaman M, Hooda Y, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh. Vaccine. 2023. PMID: 38071104. doi:10.1016/j.vaccine.2023.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。